Results 21 to 30 of about 52,949 (209)

First‐Line Osimertinib in Patients with EGFR‐Mutant Advanced Non‐Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study

The Oncologist, EarlyView., 2021
Abstract Lessons Learned Osimertinib has confirmed effectiveness in this real‐world population of patients with EGFR‐mutant advanced non‐small cell lung cancer. Thromboembolic events occur more frequently than previously reported, suggesting a thrombotic diathesis that requires further investigation. Patients with at least three metastatic sites, brain
Martina Lorenzi, Alessandra Ferro, Fabiana Cecere, Daniela Scattolin, Alessandro Del Conte, Alessandro Follador, Sara Pilotto, Valentina Polo, Mariacarmela Santarpia, Rita Chiari, Alberto Pavan, Alessandro Dal Maso, Valentina Da Ros, Giada Targato, Sabrina Vari, Stefano Indraccolo, Fiorella Calabrese, Stefano Frega, Laura Bonanno, Pier Franco Conte, Valentina Guarneri, Giulia Pasello   +21 more
wiley   +1 more source

circSETD3 Contributes to Acquired Resistance to Gefitinib in Non-Small-Cell Lung Cancer by Targeting the miR-520h/ABCG2 Pathway

Molecular Therapy: Nucleic Acids, 2020
Gefitinib is a first-line treatment for patients with non-small-cell lung cancer (NSCLC), but acquired resistance is a major obstacle to its therapeutic efficacy, and the underlying mechanisms are not fully elucidated.
Yutang Huang, Yi Dai, Chunjie Wen, Shuai He, Jingjing Shi, Dezhang Zhao, Lanxiang Wu, Honghao Zhou   +7 more
doaj   +1 more source

Lipidomics reveals that sustained SREBP-1-dependent lipogenesis is a key mediator of gefitinib-acquired resistance in EGFR-mutant lung cancer

Cell Death Discovery, 2021
Patients with EGFR mutations in non-small cell lung cancer (NSCLC) have been greatly benefited from gefitinib, however, the therapeutic has failed due to the presence of acquired resistance.
Chuncao Xu, Lei Zhang, Daifei Wang, Shiqin Jiang, Di Cao, Zhongxiang Zhao, Min Huang, Jing Jin   +7 more
doaj   +1 more source

FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer

Respiratory Research, 2020
Background This study investigated the role of fibrinogen-like protein 1 (FGL1) in regulating gefitinib resistance of PC9/GR non-small cell lung cancer (NSCLC).
Cuilan Sun, Weiwei Gao, Jiatao Liu, Hao Cheng, Jiqing Hao   +4 more
doaj   +1 more source

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer

BMC Cancer, 2007
Background Gefitinib, an oral agent of epidermal growth factor receptor tyrosine kinase inhibitor, has a certain efficacy against non-small cell lung cancer (NSCLC). Several predictive factors of gefitinib sensitivity have been well described.
Harada Masao, Sukoh Noriaki, Asahina Hajime, Konishi Jun, Kinoshita Ichiro, Yamazaki Koichi, Yokouchi Hiroshi, Akie Kenji, Ogura Shigeaki, Ishida Takashi, Munakata Mitsuru, Dosaka-Akita Hirotoshi, Isobe Hiroshi, Nishimura Masaharu   +13 more
doaj   +1 more source

Gefitinib initiates sterile inflammation by promoting IL-1β and HMGB1 release via two distinct mechanisms

Cell Death and Disease, 2021
Anticancer drug gefitinib causes inflammation-based side effects, such as interstitial pneumonitis. However, its mechanisms remain unknown. Here, we provide evidence that gefitinib elicits pro-inflammatory responses by promoting mature-interleukin-1β (IL-
Takuya Noguchi, Yuto Sekiguchi, Yuki Kudoh, Rio Naganuma, Tomohiro Kagi, Akiko Nishidate, Kazuhiro Maeda, Chizuru Ishii, Takashi Toyama, Yusuke Hirata, Gi-Wook Hwang, Atsushi Matsuzawa   +11 more
doaj   +1 more source

Pre-clinical drug-drug interaction (DDI) of gefitinib or erlotinib with Cytochrome P450 (CYP) inhibiting drugs, fluoxetine and/or losartan

Current Research in Toxicology, 2021
Objective: To evaluate drug-drug interactions (DDIs) between gefitinib or erlotinib with fluoxetine, and/or losartan. Methods: Human pooled microsomes, supersomes, and cryopreserved human hepatocytes were used to monitor DDIs in vitro.
Thu-Lan T. Luong, Michael J. McAnulty, David L. Evers, Brian J. Reinhardt, Peter J. Weina   +4 more
doaj   +1 more source

Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer. [PDF]

, 2010
PURPOSE: Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that has dramatic effects in selective patients with non-small cell lung cancer (NSCLC).
Hirofumi Nakano, Nagashima, Seiji, Tsukamoto, Kazuhiro, Fukuda, Minoru, Katsumi Nakatomi, Doi, Seiji, Takatani, Hiroshi, Shigeru Kohno, Seiji Nagashima, Minoru Fukuda, Nakano, Hirofumi, Seiji Doi, Mineyo Takasu, Kazuhiro Tsukamoto, Yoichi Nakamura, Nakamura, Yoichi, Nanae Tomonaga, Hiroshi Soda, Hiroshi Takatani, Nakatomi, Katsumi, Tomayoshi Hayashi, Takasu, Mineyo, Tomonaga, Nanae, Kohno, Shigeru, Soda, Hiroshi, Yamaguchi, Hiroyuki, Hayashi, Tomayoshi, Hiroyuki Yamaguchi   +27 more
core   +1 more source

Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines

Molecular Cancer, 2011
Background Gefitinib is a tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) especially effective in tumors with activating EGFR gene mutations while EGFR wild-type non small cell lung cancer (NSCLC) patients at present do not
Alfieri Roberta R, Galetti Maricla, Tramonti Stefano, Andreoli Roberta, Mozzoni Paola, Cavazzoni Andrea, Bonelli Mara, Fumarola Claudia, La Monica Silvia, Galvani Elena, De Palma Giuseppe, Mutti Antonio, Mor Marco, Tiseo Marcello, Mari Ettore, Ardizzoni Andrea, Petronini Pier   +16 more
doaj   +1 more source

HDGF promotes gefitinib resistance by activating the PI3K/AKT and MEK/ERK signaling pathways in non-small cell lung cancer

Cell Death Discovery, 2023
Hepatoma-derived growth factor (HDGF) expression is associated with poor prognosis in non-small cell lung cancer (NSCLC); however, whether HDGF affects gefitinib resistance in NSCLC remains unknown.
Shuyan Han, Zhihua Tian, Huifang Tian, Haibo Han, Jun Zhao, Yanna Jiao, Chunli Wang, Huifeng Hao, Shan Wang, Jialei Fu, Dong Xue, Hong Sun, Pingping Li   +12 more
doaj   +1 more source